Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KITD816V

Leukemia Research

Volumn 33, Issue 5, 2009, Pages 735-741

  Ustun, Celalettin ^a   Corless, Christopher L ^b   Savage, Natasha ^c   Fiskus, Warren ^d   Manaloor, Elizabeth ^c   Heinrich, Michael C ^b   Lewis, Grant ^a   Ramalingam, Preetha ^c   Kepten, Ilana ^b   Jillella, Anand ^a   Bhalla, Kapil ^a,d  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Department of Pathology ^*  (United States)

^d Cancer Center   (United States)

Author keywords

Acute myeloid leukemia; Asp816Val mutation; Dasatinib; KITD816V; Systemic mastocytosis; Systemic mastocytosis with associated clonal hematological non mast cell lineage disease; Tyrosine kinase inhibitor

Indexed keywords

CD34 ANTIGEN; CYTARABINE; DASATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STAT3 PROTEIN; STAT5 PROTEIN; STEM CELL FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANAMNESIS; ARTICLE; BONE LESION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; DRUG EFFECT; DRUG MEGADOSE; GENE MUTATION; HUMAN; HUMAN TISSUE; LABORATORY TEST; LYMPHADENOPATHY; MALE; MULTIPLE CYCLE TREATMENT; PANCYTOPENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYSTEMIC MASTOCYTOSIS;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; DNA PRIMERS; DNA PROBES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; PYRIMIDINES; REMISSION INDUCTION; THIAZOLES;

EID: 61449256026     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.09.027     Document Type: Article

References (20)

1. Valent P., Akin C., Escribano L., Födinger M., Hartmann K., Brockow K., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37 (2007) 435-453
2. Sperr W.R., Horny H.P., and Valent P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol 127 (2002) 140-142
3. Foster R., Griffith R., Ferrao P., and Ashman L. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. J Mol Graph Model 23 (2004) 139-152
4. Nagata H., Worobec A.S., Oh C.K., Chowdhury B.A., Tannenbaum S., Suzuki Y., et al. Identification of a point mutation in the catalytic domain of the protooncogene c-KIT in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 92 (1995) 10560-10564
5. Frost M.J., Ferrao P.T., Hughes T.P., and Ashman L.K. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-KIT whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 1 (2002) 1115-1124
6. Gleixner K.V., Mayerhofer M., Sonneck K., Gruze A., Samorapoompichit P., Baumgartner C., et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 92 (2007) 1451-1459
7. Shah N.P., Lee F.Y., Luo R., Jiang Y., Donker M., and Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108 (2006) 286-291
8. Schittenhelm M.M., Shiraga S., Schroeder A., Corbin A.S., Griffith D., Lee F.Y., et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66 (2006) 473-481
9. Verstovsek S., Ayalew T., Jorge C., O'Brien S., Garcia-Monero G., Pardani A., et al. Phase II Study of Dasatinib (SPRYCELTM) in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis [Abstract]. Blood 110 (2007) 1039a [Abstract 3551]
10. Pullarkat V.A., Bueso-Ramos C., Lai R., Kroft S., Wilson C.S., Pullarkat S.T., et al. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-KIT mutations. Am J Hematol 73 (2003) 12-17
11. Pullarkat V., Bedell V., Kim Y., Bhatia R., Nakamura R., Forman S., et al. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res 31 (2007) 261-265
12. Nagai S., Ichikawa M., Takahashi T., Sato H., Yokota H., Oshima K., et al. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukaemia. Exp Hematol 35 (2007) 1747-1752
13. Wong K.F., Chan J.K., Chan J.C., Kwong Y.L., Ma S.K., and Chow T.C. Concurrent acute myeloid leukemia and systemic mastocytosis. Am J Hematol 38 (1991) 243-244
14. Bernd H.W., Sotlar K., Lorenzen J., Osieka R., Fabry U., Valent P., et al. Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature. J Clin Pathol 57 (2004) 324-328
15. Rondoni M., Paolini S., Colarossi S., Piccaluga P.P., Papayannidis C., Palandiri F., et al. Response to dasatinib in patients with aggressive systemic mastocytosis with D816V Kit Mutation [Abstract]. Blood 110 (2007) 1042a [Abstract 3562]
16. Purtill D., Sinniah R., Cooney J., Carnley B., Cull G., Augustson B., et al. Dasatinib therapy for systemic mastocytosis: four cases. Eur J Haem 80 (2008) 456-458
17. D816V mutation treated with dasatinib (abstract(. Blood 110 (2007) 258b [Abstract 4656]
18. Gleixner K.V., Mayerhofer M., Rix U., Hoermann G., Gruze A., Krauth M.T., et al. Delineation of a KIT-Independent oncogenic pathway in neoplastic mast cells that involves Lyn and Btk, and can be disrupted by the KIT/Lyn/Btk-Targeting drug (abstract(. Blood 110 (2007) 460a [Abstract 1541]
19. Gotlib J. KIT mutations in mastocytosis and their potential as therapeutic targets. Immunol Allergy Clin North Am 26 (2006) 575-592
20. Metcalfe D.D. Regulation of normal and neoplastic human mast cell development in mastocytosis. Trans Am Clin Climatol Assoc 116 (2005) 185-203